TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28249612

Group type: EXPERIMENTAL
Intervention: Cisplatin chemo‐irradiation with SIB-IMRT, escalating total dose to the GTV up to 80.5 Gy. Chemotherapy planned either in the 1st and 5th week (cisplatin 20 mg/m2/d d 1-5 and d 29-33) or weekly (cisplatin 40 mg/m2/d) during RT. RT delivered as SIB with total doses of 80.5 Gy/70.0 Gy/56.0 Gy with 2.3 Gy/2.0 Gy and 1.6 Gy.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control arm with cisplatin chemo‐irradiation, total doses of 70.0 Gy/56.0 Gy with 2.0 Gy and 1.6 Gy.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pre-study with dose escalation up to 77.0 Gy/70.0 Gy/56.0 Gy with 2.2 Gy/2.0 Gy and 1.6 Gy.
Number of subjects: 100
Study: 26530661

Group type: EXPERIMENTAL
Intervention: Figure of eight bandage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Broad arm sling
Number of subjects: 60
Study: 24176010

Group type: EXPERIMENTAL
Intervention: 800 mg R. crenulata extract
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 21485103

Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions (MSBP)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Standard sterile barrier precautions (SSBP)
Number of subjects: 424
Study: 19968388

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Counseling as Usual (CAU)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Both MET and CAU
Number of subjects: 319
Study: 17309996

Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronic acid injections
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vehicle (isotonic sodium chloride) injections
Number of subjects: 11
Study: 15115710

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg every 3 days for 3 injections)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methylprednisolone (observational study)
Number of subjects: 20
Study: 11927728

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy in children with OSAS (N=19)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Primary snorers (PS) (N=40)
Number of subjects: 70
Study: 9862512

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) alone, 18 x 10(6) IU/m2, 24-hour i.v. infusion cycles, days 1 to 4, for 25 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) alone, 6 x 10(6) IU/m2, days 1, 3, and 5, weekly for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of IFN and IL-2, same doses as above, for 24 weeks
Number of subjects: 0
Study: 8541104

Group type: EXPERIMENTAL
Intervention: Monoclonal Lewis Y antibody (100 mg, six doses over 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo regimen (six infusions of human serum albumin)
Number of subjects: 40
Study: 2695874

Group type: EXPERIMENTAL
Intervention: Air-filled vitreous cavity
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fluid-filled vitreous cavity
Number of subjects: 51
Study: 900990

Group type: EXPERIMENTAL
Intervention: Soft X-ray radiation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mock-radiation
Number of subjects: 100
Study: 29970295

Group type: EXPERIMENTAL
Intervention: Temporary electronic gastric stimulation (EGS) using the Enterra™ system
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Permanent implantation of Enterra™ system
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-responder group
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Temporary EGS system
Number of subjects: 6
Study: 26564328

Group type: EXPERIMENTAL
Intervention: Vigorous aerobic exercise (30 minutes, 65%-75% heart rate reserve)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control session (watching a cartoon)
Number of subjects: 20
Study: 23932543

Group type: EXPERIMENTAL
Intervention: Surgically treated zygomatic complex fractures
Number of subjects: 283

Group type: COMPARATOR
Intervention: Non-surgically treated zygomatic complex fractures
Number of subjects: 283
Study: 22850121

Group type: EXPERIMENTAL
Intervention: Rifapentine 10 mg/kg/dose, administered 5 days per week for 8 weeks
Number of subjects: 531

Group type: COMPARATOR
Intervention: Rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks
Number of subjects: 531
Study: 19232887

Group type: EXPERIMENTAL
Intervention: Polished surface treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Matte surface treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polymethyl methacrylate‐coated surface treatment
Number of subjects: 80
Study: 17364900

Group type: EXPERIMENTAL
Intervention: Individual counselling plus group education
Number of subjects: 61

Group type: COMPARATOR
Intervention: Individual counselling only
Number of subjects: 61
Study: 16300701

Group type: EXPERIMENTAL
Intervention: Injection triamcinolone acetonide with lignocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Injection lignocaine alone
Number of subjects: 60
Study: 11950697

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1607
Study: 9800183

Group type: EXPERIMENTAL
Intervention: Open Airways curriculum intervention
Number of subjects: 15
Study: 8542460

Group type: EXPERIMENTAL
Intervention: Orally administered sodium cromoglycate
Number of subjects: 0
Study: 2611040

Group type: EXPERIMENTAL
Intervention: Immunotherapy (corynebacterium parvum s.c. around the scar 2 weeks after mastectomy) in node negative patients
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: CMF for 1 year in node positive patients
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Combination of immunotherapy and CMF in node positive patients
Number of subjects: 1116

Group type: COMPARATOR
Intervention: No further adjuvant therapy in node positive patients
Number of subjects: 1116

Group type: COMPARATOR
Intervention: No further adjuvant therapy in node negative patients
Number of subjects: 1116
Study: 611325

Group type: EXPERIMENTAL
Intervention: Experimental group (30 subjects) subjected to workload tests on the bicycle ergometer, starting at a 600 kpm workload and increasing by 150 kpm each day until a heart rate near 165 bpm was reached.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Validation group (30 subjects) administered the Astrand‐Rhyming Test using the established multiple regression equation to predict workload.
Number of subjects: 60
Study: 30819011

Group type: EXPERIMENTAL
Intervention: School dropout
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fewer days of school attendance
Number of subjects: 100
Study: 27707615

Group type: EXPERIMENTAL
Intervention: Prone positioning <2 hours
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prone positioning >2 hours
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Supine positioning
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups (prone <2h, prone >2h, supine)
Number of subjects: 120
Study: 25449393

Group type: EXPERIMENTAL
Intervention: Moderate altitude (Davos Jakobshorn at 2590 m)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low altitude (Zurich at 490 m)
Number of subjects: 0
Study: 23302544

Group type: COMPARATOR
Intervention: Diet-only group (DI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diet and exercise group (DI + EXE)
Number of subjects: 48
Study: 21499770

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% added to travoprost
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% added to travoprost
Number of subjects: 253
Study: 18808335

Group type: EXPERIMENTAL
Intervention: DNA priming vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MVA boosting vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 mg of HIV‐1 DNA administered intradermally
Number of subjects: 40
Study: 17196045

Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Venlafaxine XR (225 mg/day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg/day) at maximum dose for 3 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Venlafaxine XR (225 mg/day) at maximum dose for 3 weeks
Number of subjects: 160
Study: 12689612

Group type: EXPERIMENTAL
Intervention: Fenfluramine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 10611186

Group type: EXPERIMENTAL
Intervention: Long GnRHa/HMG protocol with luteal support by repeated HCG (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Early follicular phase cessation of GnRHa without luteal support (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long GnRHa protocol without luteal support (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group of 40 normo-ovulatory women
Number of subjects: 60
Study: 9194725

Group type: EXPERIMENTAL
Intervention: Presence of 5 or more drusen
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Focal hyperpigmentation
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Presence of 1 or more large drusen
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Definite systemic hypertension
Number of subjects: 670

Group type: COMPARATOR
Intervention: No risk factors
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: All 4 risk factors present
Number of subjects: 670
Study: 8184498

Group type: EXPERIMENTAL
Intervention: Intensive back training
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional back training
Number of subjects: 96
Study: 2440159

Group type: EXPERIMENTAL
Intervention: 250 ml Pentastarch
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 ml Pentastarch
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1000 ml Pentastarch
Number of subjects: 12
Study: 29673974

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Supportive Care (SC)
Number of subjects: 61
Study: 25047162

Group type: EXPERIMENTAL
Intervention: Translig transverse crosspin
Number of subjects: 118

Group type: COMPARATOR
Intervention: ToggleLoc with ZipLoop technology
Number of subjects: 118
Study: 22893231

Group type: EXPERIMENTAL
Intervention: Pay for performance (P4P) condition
Number of subjects: 986

Group type: COMPARATOR
Intervention: Implementation-as-usual (IAU) control condition
Number of subjects: 986
Study: 20528891

Group type: EXPERIMENTAL
Intervention: Autologous bone (AB) chips
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ossix membrane (OM)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination of AB chips and OM
Number of subjects: 92

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 92

Group type: COMPARATOR
Intervention: Younger patients (<50 years)
Number of subjects: 92
Study: 18826532

Group type: EXPERIMENTAL
Intervention: Family Check‐Up and linked parenting support services
Number of subjects: 731
Study: 15910157

Group type: EXPERIMENTAL
Intervention: Novel word labeling with conceptual descriptions (artifacts and animates)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Novel word labeling with conceptual descriptions
Number of subjects: 2
Study: 12873912

Group type: EXPERIMENTAL
Intervention: 10% DCLHb (n = 92)
Number of subjects: 181

Group type: COMPARATOR
Intervention: 3 U of packed red blood cells (PRBCs) (n = 89)
Number of subjects: 181
Study: 10392982

Group type: EXPERIMENTAL
Intervention: Intensive case management (case load 10-15 per case manager)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Standard case management (case load 30-35 per case manager)
Number of subjects: 708
Study: 7727091

Group type: EXPERIMENTAL
Intervention: Silastic tympanostomy tubes impregnated with silver oxide
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control ears with standard Silastic tubes
Number of subjects: 125
Study: 2104531

Group type: EXPERIMENTAL
Intervention: Silicone cream with 20% silicone oil and occlusive dressing technique
Number of subjects: 47

Group type: COMPARATOR
Intervention: Simple application of silicone cream
Number of subjects: 47
Study: 6997360

Group type: EXPERIMENTAL
Intervention: 0.25% proparacaine
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: 0.2% benoxinate
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: 0.125% proparacaine
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Lower doses of anesthetic
Number of subjects: 361
Study: 31030100

Group type: EXPERIMENTAL
Intervention: rhTPO + THD
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: THD monotherapy
Number of subjects: 17
Study: 29234055

Group type: EXPERIMENTAL
Intervention: OIT combined with 24 weeks of omalizumab (OMB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 16
Study: 25597862

Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg once daily
Number of subjects: 268

Group type: COMPARATOR
Intervention: Silodosin 4 mg twice daily
Number of subjects: 268
Study: 22841433

Group type: EXPERIMENTAL
Intervention: Description condition (payoff matrix)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experience condition (learned payoffs through experience)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intergroup Prisoner's Dilemma with Intragroup Power Dynamics
Number of subjects: 0
Study: 21161265

Group type: EXPERIMENTAL
Intervention: PRT + usual care (n = 24)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care control (n = 25)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 49
Study: 19531419

Group type: EXPERIMENTAL
Intervention: 2-g amoxicillin tablets 1 hour before surgery
Number of subjects: 59

Group type: COMPARATOR
Intervention: No antibiotic therapy (Control)
Number of subjects: 59
Study: 16754935

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 632

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: MR (maintenance rituximab)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: CHOP + MR
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: R-CHOP + MR
Number of subjects: 632
Study: 15111272

Group type: EXPERIMENTAL
Intervention: DSS (dioctyl sodium sulfosuccinate) applied topically every 2 hours during outbreaks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo applied topically every 2 hours during outbreaks
Number of subjects: 32
Study: 11696709

Group type: EXPERIMENTAL
Intervention: Percutaneous stone removal
Number of subjects: 128

Group type: COMPARATOR
Intervention: Shock wave lithotripsy
Number of subjects: 128
Study: 9156038

Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GHRP-6 (1 microgram/kg i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-6
Number of subjects: 21
Study: 7828613

Group type: EXPERIMENTAL
Intervention: Single-slice rectangular ROIs in frontal, temporal, temporoparietal, and occipital cortices
Number of subjects: 108

Group type: COMPARATOR
Intervention: Single-slice and multi-slice ROIs with reference to normal anatomy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SPET using technetium‐99m d,l‐hexamethylpropylene amine oxime (99mTc‐HMPAO)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rectangular ROIs
Number of subjects: 108
Study: 3341336

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ranitidine vs. Cimetidine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ADU vs. IDU
Number of subjects: 3
Study: 31656059

Group type: EXPERIMENTAL
Intervention: FENO-guided algorithm (inhaled corticosteroid (ICS) dose adjusted according to FENO with long-acting beta-agonist (LABA) added for uncontrolled symptoms)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Symptom control algorithm (control group)
Number of subjects: 220
Study: 29986662

Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Pictorial brochure
Number of subjects: 1200
Study: 28557903

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 70
Study: 26136594

Group type: EXPERIMENTAL
Intervention: Higher serum 25(OH)D concentrations
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Lower plasma glucose concentrations
Number of subjects: 217

Group type: COMPARATOR
Intervention: Serum 25(OH)D and plasma insulin concentrations
Number of subjects: 217

Group type: COMPARATOR
Intervention: Plasma glucose
Number of subjects: 217
Study: 23532808

Group type: EXPERIMENTAL
Intervention: Sleeper One(®)
Number of subjects: 112

Group type: COMPARATOR
Intervention: WAND(®)
Number of subjects: 112
Study: 20929998

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with olive oil (1 liter/week)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with nuts (30 g/day)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control group (low-fat diet)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Combined Mediterranean diets (with olive oil and nuts)
Number of subjects: 418
Study: 17678911

Group type: EXPERIMENTAL
Intervention: recombinant FSH (75-150 IU/d) + GnRH antagonist (0.25 mg/d)
Number of subjects: 367

Group type: COMPARATOR
Intervention: recombinant FSH (75-150 IU/d) alone
Number of subjects: 367
Study: 16573259

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream plus clindamycin 1%/benzoyl peroxide 5% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tazarotene 0.1% cream
Number of subjects: 0
Study: 14574651

Group type: EXPERIMENTAL
Intervention: Severe smoke inhalation cases
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of cases to controls
Number of subjects: 22
Study: 10764848

Group type: EXPERIMENTAL
Intervention: Presenting visual acuity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Refractive error under cycloplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amblyopia assessment
Number of subjects: 0
Study: 8831648

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 36
Study: 1331618

Group type: EXPERIMENTAL
Intervention: Structured interview regarding risk behavior
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Interview plus one group AIDS education session
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Interview, AIDS education plus optional HIV testing
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Alcohol users
Number of subjects: 313

Group type: COMPARATOR
Intervention: Nondrinkers
Number of subjects: 313
Study: 6382224

Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg twice a day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: mefruside 25 mg once a day
Number of subjects: 20
Study: 31829187

Group type: EXPERIMENTAL
Intervention: Organic rumen‐protected fat (RPF) supplement (0.45 kg/d)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control pellets (CON)
Number of subjects: 202
Study: 29342058

Group type: EXPERIMENTAL
Intervention: Capsular repair
Number of subjects: 15

Group type: COMPARATOR
Intervention: No capsular repair
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (Repaired and Unrepaired)
Number of subjects: 15
Study: 27208823

Group type: EXPERIMENTAL
Intervention: TRL from MetS patients with endothelial dysfunction (n=6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TRL from both MetS groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TRL from MetS patients with endothelial dysfunction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TRL-triglyceride (%)
Number of subjects: 40
Study: 25556460

Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with DCF chemotherapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard DCF chemotherapy
Number of subjects: 34
Study: 22483480

Group type: EXPERIMENTAL
Intervention: Early ureteric stent removal at 8 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine ureteric stent removal at 15 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with bacteriuria
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bacteriuria causative organisms
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ESBL producing organisms
Number of subjects: 90
Study: 17393217

Group type: EXPERIMENTAL
Intervention: DHA-functional food (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study: 15951292

Group type: EXPERIMENTAL
Intervention: High-dose sequential (HDS) chemotherapy plus high-dose mitoxantrone and melphalan with autologous stem-cell transplantation (ASCT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Outpatient dose-dense chemotherapy regimen (MegaCEOP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: High-dose sequential (HDS) chemotherapy plus ASCT
Number of subjects: 130
Study: 12492248

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 944

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 944
Study: 9579297

Group type: EXPERIMENTAL
Intervention: naphtoxazine (SDZ‐NVI‐085)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 7659407

Group type: EXPERIMENTAL
Intervention: 0.60% NaCl solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.45% NaCl solution
Number of subjects: 12
Study: 2719727

Group type: EXPERIMENTAL
Intervention: 750 rads of lymphoid irradiation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2,000 rads of lymphoid irradiation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 20
Study: 30265319

Group type: EXPERIMENTAL
Intervention: P. spumarius nymphs
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Plant infestation rate in Lecce province (infected area)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Host plant selection
Number of subjects: 72
Study: 28216190

Group type: EXPERIMENTAL
Intervention: Cognitive messaging iBook
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Affective messaging video
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106